NEWPORT BEACH, Calif., March 18, 2021 — CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a webinar to continue educating the Duchenne community about the COVID-19 vaccines. Part of their COVID-19 education initiative which launched in January, this webinar will focus...
Latest News
NEWPORT BEACH, Calif. – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, today launched a supplemental newborn screening initiative for Duchenne muscular dystrophy, a rare genetic disorder. The partnership between CureDuchenne and Brigham and Women’s Hospital is the first program to offer supplemental newborn screening...
BOSTON – CureLab Oncology, a clinical-stage biotech company, has been granted a US patent for the application of its lead product for the treatment of ALS, Alzheimer’s, Huntington’s, and Parkinson’s disease. These patent applications were already granted in Asia and Europe. Today, 5 million Americans suffer from Alzheimer’s, 1 million from Parkinson’s, 30,000...
BOSTON, Mass. – CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been shown to significantly enhance standard chemotherapy and provides clinical benefits for the patients with the deadliest form ovarian cancer. Elenagen belongs to a novel class of biological agents, supercoiled circular DNA...
LOS ANGELES, CA – CureSHANK will award a total of $250,000 aimed at stimulating research on SHANK3-related epilepsy, prevalent in Phelan-McDermid syndrome patients. The grants, CureSHANK Research to Cure Grant: Epilepsy (R2C Epilepsy), will provide targeted funding to support SHANK3-related epilepsy research projects. The awards aim to improve mechanistic and...
PALO ALTO, Calif. — Curio Bioscience today announced the commercialization of the world’s first technology that spatially contextualizes single-cell sequencing data, leveraging a breakthrough invention called Slide-tags developed by the Broad Institute of MIT and Harvard and published in Nature this past December. The first stage of Curio’s commercialization of...
DAEJEON, South Korea — Curocell, South Korea based CAR-T specialized company (CEO: Gunsoo Kim), has completed Phase 2 clinical trial for its next-generation CD19 CAR-T therapy “Anbal-cel” that targets relapsed or refractory DLBCL (Diffuse Large B-cell Lymphoma). This announcement is a significant milestone and is paving the way towards the launch...
Cambridge, UK – Whole genome sequencing has improved clinical care of some children with cancer in England by informing individual patient care. New research from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Trust, Great Ormond Street Hospital, and the University of Cambridge, supports the efforts to provide genome sequencing...
Toulouse, France – CVasThera, a biopharmaceutical company that specializes in the development of novel therapies for cardiovascular and bowel pathologies, today announces it has secured €1.3 million ($1.6M) in financial backing in its first funding round. These funds will triple the company’s equity and capital. It will enable CVasThera to...
On Tuesday, students at Cottonwood Elementary School (CWE) recognized Rare Disease Day, a day is hosted on the last day of February. The day aims to raise awareness for rare diseases and improve access to treatment and medical representation for individuals that have rare diseases. Cottonwood’s Mrs. Sitterud visited each...